Xeris Biopharma Director Sells 107,500 Shares at $7.32 Per Share on August 13.
ByAinvest
Friday, Aug 15, 2025 5:17 pm ET1min read
XERS--
The sale was reported through the SEC Filing Form 4, which is a standard form used by corporate insiders to report transactions in company securities. This filing provides transparency and helps investors make informed decisions.
This transaction follows the recent market trends and the overall performance of Xeris Biopharma Holdings, Inc. As of the current date, the stock price remains steady, reflecting the company's ongoing efforts in biopharmaceutical research and development.
For more details, refer to the SEC filing [1].
References:
[1] https://www.tradingview.com/news/tradingview:4113513c36a72:0-xeris-biopharma-holdings-director-sells-107-500-shares/
Xeris Biopharma Holdings, Inc. [XERS] recently announced that Director Johnson John has sold 107,500 shares at a price of $7.32 per share on August 13, 2025.
Xeris Biopharma Holdings, Inc. [XERS] recently announced that Director Johnson John sold 107,500 shares of the company's Common Stock on August 13, 2025. The transaction was executed at a weighted average price of $7.3159 per share, totaling $786,459. Following this sale, Johnson directly owns 833,483 shares of the company.The sale was reported through the SEC Filing Form 4, which is a standard form used by corporate insiders to report transactions in company securities. This filing provides transparency and helps investors make informed decisions.
This transaction follows the recent market trends and the overall performance of Xeris Biopharma Holdings, Inc. As of the current date, the stock price remains steady, reflecting the company's ongoing efforts in biopharmaceutical research and development.
For more details, refer to the SEC filing [1].
References:
[1] https://www.tradingview.com/news/tradingview:4113513c36a72:0-xeris-biopharma-holdings-director-sells-107-500-shares/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet